Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Gain Therapeutics, Inc. (GANX : NSDQ)

• Company Description    Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain Therapeutics Inc. is based in BETHESDA, Md. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $1.26 Daily Weekly Monthly 20 Day Moving Average: 665,692 shares Shares Outstanding: 43.64 (millions) Market Capitalization: $54.99 (millions) Beta: 0.19 52 Week High: $4.34 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.52% -30.80% 12 Week -28.41% -30.16% Year To Date -60.87% -64.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4800 MONTGOMERY LANE SUITE 220 - BETHESDA,MD 20814 USA ph: 301-500-1556 fax: - ir@gaintherapeutics.com http://www.gaintherapeutics.com

• General Corporate Information    Officers Gene Mack - Chief Executive Officer and Director Khalid Islam - Chairman Gianluca Fuggetta - Senior Vice President Finance Dov Goldstein - Director Hans Peter Hasler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 36269B105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 43.64 Most Recent Split Date: (:1) Beta: 0.19 Market Capitalization: $54.99 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 42.11% vs. Previous Quarter: 15.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -161.59 03/31/26 - -201.44 ROA 09/30/26 - - 06/30/26 - -118.36 03/31/26 - -136.24 Current Ratio 09/30/26 - - 06/30/26 - 4.36 03/31/26 - 4.69 Quick Ratio 09/30/26 - - 06/30/26 - 4.36 03/31/26 - 4.69 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 0.26 03/31/26 - 0.33 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.02 03/31/26 - 0.02 Debt-to-Capital 09/30/26 - - 06/30/26 - 1.91 03/31/26 - 1.91

Powered by Zacks Investment Research ©